Perspectives
David Lassen Shares Insights on Prime/MRx Analysis on GLP-1 for Weight Loss in New Video
October 31, 2023Earlier this year, Prime Therapeutics/Magellan Rx (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.
WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study
As GLP-1a drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts